Reports Q3 revenue $830,000 vs $451,000 last year. “Our existing royalty portfolio continues to mature, driven by increasing cash receipts of VABYSMO and IXINITY and the advancement of several assets, most notably the New Drug Application filing of tovorafenib by Day One Biopharmaceuticals,” stated Owen Hughes, Executive Chairman of XOMA. “With additional regulatory and development milestones forthcoming by year-end, we believe a solid foundation for future growth is upon us.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XOMA:
- XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
- Is XOMA a Buy, Before Earnings?
- Xoma earns $5M milestone upon FDA acceptance of Day One’s tovorafenib NDA
- XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- ObsEva: Xoma will be receiving full worldwide rights on ebopiprant